TH 1040 3 Kite Pharma FINAL.Pdf
Total Page:16
File Type:pdf, Size:1020Kb
Jefferies Global Healthcare Conference November 20, 2014 Forward Looking Statements / Safe Harbor To the extent statements contained in this presentation are not descriptions of historical facts regarding Kite Pharma, Inc. (“Kite,” “we,” “us,” or “our”), they are forward- looking statements reflecting management’s current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward- looking statements contained in this presentation include, but are not limited to, statements regarding: (i) the success, cost and timing of our product development activities and clinical trials; (ii) the ability and willingness of the National Cancer Institute (NCI) to continue research and development activities relating to our product candidates; (iii) our ability to obtain and maintain regulatory approval of KTE-C19 and any other product candidates; (iv) the ability to license additional rights relating to product candidates and to comply with our existing license agreements; (v) our ability to obtain funding for our operations and further development and commercialization of our product candidates; (vi) the commercialization of our product candidates, if approved; (vii) our plans to research, develop and commercialize our product candidates; (viii) future agreements with third parties in connection with the commercialization and supply of our product candidates and any otherapproved product; (ix) the size and growth potential of the markets for our product candidates, and our ability to serve those markets; (x) the rate and degree of market acceptance of our product candidates; (xi) our ability to attract and retain key scientific or management personnel; (xii) the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; (xiii) our use of proceeds from this contemplated offering; and (xiv) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates. Various factors may cause differences between our expectations and actual results. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This presentation is made pursuant to Section 5(d) of the U.S. Securities Act of 1933, as amended (“test-the-waters”), and is intended solely for investors that are either qualified institutional buyers or institutions that are accredited investors (as such terms are defined under SEC rules) solely for the purpose of determining whether such investors might have an interest in a securities offering contemplated by us. Any such offering of securities will only be made by means of a registration statement (including a preliminary prospectus) filed with the SEC, after such registration statement is filed and meets the requirements of the U.S. Securities Act of 1933, as amended. No such registration statement has been filed, as of the date of this presentation. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer,solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 2 KITE PHARMA, INC. Kite Pharma Overview Cancer Immunotherapy using Engineered Autologous Cell Therapy (eACTTM) • 45 employees, including 28 R&D • 20,000 sq. feet + R&D labs • Broad IP, with a dominant CAR technology estate • Streamlined and rapid eACT ™ manufacturing process Santa Monica , Ca 3 KITE PHARMA, INC. Kite Pharma — Milestones 2008 2009 2010 2011 2012 2013 2014 2015 KITE PHARMA CRADA IP Estate Accelerated (NCI) IPO clinical FOUNDED Secured development KTE-C19 NCI TCR Clinical Data NCI CAR Clinical Data NCI First CAR Therapy (anti-CD19) NCI First TCR Therapies Kite Series A Science 342: 1433, Dec 2013 4 KITE PHARMA, INC. Inventors & Clinical Pioneer - CAR T Cells Zelig Eshhar, Ph.D. (Member Scientific Advisor Board) • Chairman of Immunology Research, Sourasky Medical Center, Tel Aviv • Professor Emeritus, Weizmann Institute of Science, Israel Margo R. Roberts, Ph.D. • Chief Scientific Officer, Kite Pharma, Inc. • Inventor on 16 US patents and patent applications related to CAR T cell technology and tumor vaccine therapies Steven Rosenberg, M.D., Ph.D. • Chief of Surgery, NCI • Professor of Surgery, Uniformed Services University of Health Sciences and George Washington University School of Medicine and Health Sciences 5 KITE PHARMA, INC. Evolution of CAR Technology and its IP 6 KITE PHARMA, INC. Kite Intellectual Property Estate • Dominant IP position for CAR technology through 2027 • Broadest claims for all scFv-based CAR constructs − Patent estate consolidates the CAR IP from Z. Eshhar, Yeda-Weizmann, NCI, UCSF, and Cell Genesys and includes the two lead patents (Eshhar 7,741,465 and Roberts 5,712,149) • Expanding portfolio of specific TCR/CAR products • EGFRvIII, NY-ESO-1, SSX2, and others • Optimized and closed system manufacturing processes 7 KITE PHARMA, INC. Leadership Team with Extensive Industry Expertise Arie Belldegrun, M.D., FACS UCLA, Teva, Arno, Cougar, Agensys, NCI Founder, Chairman, President, CEO Cynthia M. Butitta, MBA NextWave, Telik, Connetics COO and CFO David D. Chang, M.D., Ph.D. Amgen, UCLA EVP R&D, CMO Helen S. Kim NGM Biopharmaceuticals, Kosan, Onyx, Chiron EVP, Business Development Margo R. Roberts, Ph.D. University of Virginia, Cell Genesys Chief Scientific Officer Jeffrey Wiezorek, M.D., M.S. Amgen, UCLA, California Institute of Technology VP, Clinical Development Marc Better, Ph.D. Boehringer Ingelheim, Amgen, Abgenix, XOMA VP, Product Sciences 8 KITE PHARMA, INC. Kite Clinical Development Team David D. Chang, M.D., Ph.D. Amgen, UCLA Executive Vice President, R&D, CMO Jeff Wiezorek, M.D., M.S. Amgen, UCLA, Caltech Vice President, Clinical Development Adrian Bot, M.D., Ph.D. MannKind, Mount Sinai Vice President, Translational Medicine Will Go, M.D., Ph.D. Amgen, UCSD Senior Director, Clinical Development Rajul Jain, M.D. Amgen, MD Anderson, Rockefeller Senior Director, Clinical Development Jeff Aycock, B.A. Amgen, Pfizer Senior Director, Clinical Operations Lynn Navale Amgen, Baxter Bioscience Senior Director, Biostatistics 9 KITE PHARMA, INC. Scientific Advisory Board: World Leaders in Cancer Immunotherapy Owen Witte, M.D. – Chair Ronald Levy, M.D. • Distinguished Professor of Microbiology, • Robert K Summy and Helen K Summy Immunology and Molecular Genetics, UCLA Professor of Medicine, Stanford University • Howard Hughes Investigator • Director, Lymphoma Program, Stanford University • Member, National Academy of Sciences • Member, National Academy of Sciences James Economou, M.D., Ph.D. Antoni Ribas, M.D., Ph.D. • Beaumont Professor of Surgery and Chief, • Director, Tumor Immunology Program, Division of Surgical Oncology, UCLA Jonsson Comprehensive Cancer Care • Vice Chancellor for Research, UCLA Center, UCLA • Professor of Medicine, Hematology/ Donald Kohn, M.D. Oncology, UCLA • Professor of Microbiology, Immunology and Molecular Genetics & Pediatric Inder Verma, Ph.D. Hematology/Oncology, UCLA • Director, Helmsley Center for Genomic • Director, Human Gene and Cell Therapy Medicine, Salk Institute Program, UCLA • Professor of Genetics, Salk Institute • Member, Broad Stem Cell Research Center & • Member, National Academy of Sciences Jonsson Comprehensive Cancer Center 10 KITE PHARMA, INC. Engineered Autologous T Cell Therapy (eACTTM) Transformational Cancer Therapy Key Advantages • The ultimate personalized therapy • Living treatment, expands in the body • Durable remission with a single treatment • CAR products combine the specificity of antibodies with the killing capacity of T cells • TCR products directs T cells to intracellular tumor targets in a HLA specific manner • Broad applications, including chemo-refractory tumors 11 KITE PHARMA, INC. Broad eACTTM Portfolio — Both CAR & TCR Chimeric Antigen Receptor (CAR) Products T Cell Receptor (TCR) Products Target molecules on cell surface Target molecules are intracellular HLA-restricted 12 KITE PHARMA, INC. Exclusive CRADA with NCI CRADA • Pioneering research Product • Manufacturing • Product & process design • Clinical development • Early clinical evaluation Selection* • Commercialization Why NCI Surgery Branch? • Significant experience and leadership in T cell therapy; large and dedicated team • Rich pipeline of CAR and TCR products • Product selection based on human rather than mouse data 13 * Through right to negotiate license for IP related to products KITE PHARMA, INC. Simple Manufacturing Process Apheresis Product T cell separation Ready for bedside use Viral Cell transfer to transduction bag for growth Wash, Concentrate Expand & Freeze cells 14 KITE PHARMA, INC. Streamlined and Rapid eACT ™ Manufacturing Process for anti-CD19 CAR T Cells • Technology transfer to contract vendors